Cargando…

HLA-B(*)58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand

Background: The aim of this study was to investigate the predisposition to different types of allopurinol-induced cutaneous adverse drug reactions (CADR), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN; SJS-TEN, n = 13), drug reaction with eosinophilia and systemic symptom...

Descripción completa

Detalles Bibliográficos
Autores principales: Sukasem, Chonlaphat, Jantararoungtong, Thawinee, Kuntawong, Parnrat, Puangpetch, Apichaya, Koomdee, Napatrupron, Satapornpong, Patompong, Supapsophon, Patcharin, Klaewsongkram, Jettanong, Rerkpattanapipat, Ticha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947582/
https://www.ncbi.nlm.nih.gov/pubmed/27486401
http://dx.doi.org/10.3389/fphar.2016.00186
_version_ 1782443190167535616
author Sukasem, Chonlaphat
Jantararoungtong, Thawinee
Kuntawong, Parnrat
Puangpetch, Apichaya
Koomdee, Napatrupron
Satapornpong, Patompong
Supapsophon, Patcharin
Klaewsongkram, Jettanong
Rerkpattanapipat, Ticha
author_facet Sukasem, Chonlaphat
Jantararoungtong, Thawinee
Kuntawong, Parnrat
Puangpetch, Apichaya
Koomdee, Napatrupron
Satapornpong, Patompong
Supapsophon, Patcharin
Klaewsongkram, Jettanong
Rerkpattanapipat, Ticha
author_sort Sukasem, Chonlaphat
collection PubMed
description Background: The aim of this study was to investigate the predisposition to different types of allopurinol-induced cutaneous adverse drug reactions (CADR), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN; SJS-TEN, n = 13), drug reaction with eosinophilia and systemic symptoms (DRESS, n = 10) and Maculopapular eruption (MPE; n = 7), conferred by HLA-B(*)58:01 in a Thai population. Methods: This case-control association study compares 30 patients with allopurinol-induced CADR, allopurinol-tolerant control patients (n = 100), and a Thai general population (n = 1095). Patients' human leukocyte antigen type B (HLA-B) alleles were genotyped by using a two-stage sequence-specific oligonucleotide probe system. Results: Of a total 30 patients with CADR due to allopurinol, 29 (96.7%) patients were found to be at least heterozygous for HLA-B(*)58:01, compared to only 4.0% in allopurinol-tolerant patients (p < 0.001). Odds ratio (OR) for the association of HLA-B(*)58:01 with allopurinol-induced CADR in this population was 696.0 (95% CI: 74.8–6475.0). The HLA-B(*)58:01 allele was present in all patients with allopurinol-induced SJS-TEN (OR = 579.0, 95%CI: 29.5–11362.7, p < 0.001) and DRESS (OR 430.3, 95%CI: 22.6–8958.9, p < 0.001). Additionally, OR of HLA-B(*)58:01 was highly significant in the allopurinol-induced MPE patients (OR 144.0, 95%CI: 13.9–1497.0, p < 0.001). Conclusion: In this study we confirmed the association between HLAB(*)58:01 and allopurinol-induced SJS-TEN in a Thai population. In addition, we identified an association between HLA-B(*)58:01 and allopurinol-induced DRESS and MPE in this population. Therefore, HLA-B(*)58:01 can be used as a pharmacogenetic marker for allopurinol-induced CADR including SJS-TEN, DRESS and MPE. These results suggest that screening for HLA-B(*)58:01 alleles in patients who will be treated with allopurinol would be clinically helpful in preventing the risk of developing CARD in a Thai patients. Summary: Regardless of phenotype, this is the first pharmacogenetic study of allopurinol-induced CADR in patients of Thai ancestry. In this study we confirmed the association between HLA-B(*)58:01 and allopurinol-induced SJS-TEN, DRESS, and MPE in Thai population. Regarding to our findings, the pharmacogenetic interpretation could be generalized to drug hypersensitivity including DRESS, SJS-TEN, and MPE.
format Online
Article
Text
id pubmed-4947582
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-49475822016-08-02 HLA-B(*)58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand Sukasem, Chonlaphat Jantararoungtong, Thawinee Kuntawong, Parnrat Puangpetch, Apichaya Koomdee, Napatrupron Satapornpong, Patompong Supapsophon, Patcharin Klaewsongkram, Jettanong Rerkpattanapipat, Ticha Front Pharmacol Pharmacology Background: The aim of this study was to investigate the predisposition to different types of allopurinol-induced cutaneous adverse drug reactions (CADR), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN; SJS-TEN, n = 13), drug reaction with eosinophilia and systemic symptoms (DRESS, n = 10) and Maculopapular eruption (MPE; n = 7), conferred by HLA-B(*)58:01 in a Thai population. Methods: This case-control association study compares 30 patients with allopurinol-induced CADR, allopurinol-tolerant control patients (n = 100), and a Thai general population (n = 1095). Patients' human leukocyte antigen type B (HLA-B) alleles were genotyped by using a two-stage sequence-specific oligonucleotide probe system. Results: Of a total 30 patients with CADR due to allopurinol, 29 (96.7%) patients were found to be at least heterozygous for HLA-B(*)58:01, compared to only 4.0% in allopurinol-tolerant patients (p < 0.001). Odds ratio (OR) for the association of HLA-B(*)58:01 with allopurinol-induced CADR in this population was 696.0 (95% CI: 74.8–6475.0). The HLA-B(*)58:01 allele was present in all patients with allopurinol-induced SJS-TEN (OR = 579.0, 95%CI: 29.5–11362.7, p < 0.001) and DRESS (OR 430.3, 95%CI: 22.6–8958.9, p < 0.001). Additionally, OR of HLA-B(*)58:01 was highly significant in the allopurinol-induced MPE patients (OR 144.0, 95%CI: 13.9–1497.0, p < 0.001). Conclusion: In this study we confirmed the association between HLAB(*)58:01 and allopurinol-induced SJS-TEN in a Thai population. In addition, we identified an association between HLA-B(*)58:01 and allopurinol-induced DRESS and MPE in this population. Therefore, HLA-B(*)58:01 can be used as a pharmacogenetic marker for allopurinol-induced CADR including SJS-TEN, DRESS and MPE. These results suggest that screening for HLA-B(*)58:01 alleles in patients who will be treated with allopurinol would be clinically helpful in preventing the risk of developing CARD in a Thai patients. Summary: Regardless of phenotype, this is the first pharmacogenetic study of allopurinol-induced CADR in patients of Thai ancestry. In this study we confirmed the association between HLA-B(*)58:01 and allopurinol-induced SJS-TEN, DRESS, and MPE in Thai population. Regarding to our findings, the pharmacogenetic interpretation could be generalized to drug hypersensitivity including DRESS, SJS-TEN, and MPE. Frontiers Media S.A. 2016-07-18 /pmc/articles/PMC4947582/ /pubmed/27486401 http://dx.doi.org/10.3389/fphar.2016.00186 Text en Copyright © 2016 Sukasem, Jantararoungtong, Kuntawong, Puangpetch, Koomdee, Satapornpong, Supapsophon, Klaewsongkram and Rerkpattanapipat. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Sukasem, Chonlaphat
Jantararoungtong, Thawinee
Kuntawong, Parnrat
Puangpetch, Apichaya
Koomdee, Napatrupron
Satapornpong, Patompong
Supapsophon, Patcharin
Klaewsongkram, Jettanong
Rerkpattanapipat, Ticha
HLA-B(*)58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand
title HLA-B(*)58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand
title_full HLA-B(*)58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand
title_fullStr HLA-B(*)58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand
title_full_unstemmed HLA-B(*)58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand
title_short HLA-B(*)58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand
title_sort hla-b(*)58:01 for allopurinol-induced cutaneous adverse drug reactions: implication for clinical interpretation in thailand
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947582/
https://www.ncbi.nlm.nih.gov/pubmed/27486401
http://dx.doi.org/10.3389/fphar.2016.00186
work_keys_str_mv AT sukasemchonlaphat hlab5801forallopurinolinducedcutaneousadversedrugreactionsimplicationforclinicalinterpretationinthailand
AT jantararoungtongthawinee hlab5801forallopurinolinducedcutaneousadversedrugreactionsimplicationforclinicalinterpretationinthailand
AT kuntawongparnrat hlab5801forallopurinolinducedcutaneousadversedrugreactionsimplicationforclinicalinterpretationinthailand
AT puangpetchapichaya hlab5801forallopurinolinducedcutaneousadversedrugreactionsimplicationforclinicalinterpretationinthailand
AT koomdeenapatrupron hlab5801forallopurinolinducedcutaneousadversedrugreactionsimplicationforclinicalinterpretationinthailand
AT satapornpongpatompong hlab5801forallopurinolinducedcutaneousadversedrugreactionsimplicationforclinicalinterpretationinthailand
AT supapsophonpatcharin hlab5801forallopurinolinducedcutaneousadversedrugreactionsimplicationforclinicalinterpretationinthailand
AT klaewsongkramjettanong hlab5801forallopurinolinducedcutaneousadversedrugreactionsimplicationforclinicalinterpretationinthailand
AT rerkpattanapipatticha hlab5801forallopurinolinducedcutaneousadversedrugreactionsimplicationforclinicalinterpretationinthailand